CoChat

Polymeric Nanoparticles for Nasal Drug Delivery to the Brain: Relevance to Alzheimer's Disease

Rabiee, Navid, Ahmadi, Sepideh, Afshari, Ronak, Khalaji, Samira, Rabiee, Mohammad, Bagherzadeh, Mojtaba, Fatahi, Yousef, Dinarvand, Rassoul, Tahriri, Mohammadreza, Tayebi, Lobat, Hamblin, Michael R., Webster, Thomas J. · 2021 · Advanced Therapeutics
Cited by 140

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Abstract

Currently, Alzheimer's disease (AD) accounts for more than half of all dementia cases. Although genetics, age, and environmental factors affect the disease, the cause of AD is not yet fully known. Various drugs have been proposed for the prevention and treatment of AD, but the delivery of these therapeutic agents to the brain is difficult. The blood–brain barrier prevents systemic drugs from accessing the central nervous system and designing a suitable system to overcome this barrier has attracted much attention. The intranasal pathway, given its proximity to the brain, provides a great opportunity for drug delivery. Understanding the physiological characteristics of the nose can be useful in selecting the appropriate carrier and material. Some of the emerging vehicles used for nose‐to‐brain delivery of anti‐AD drugs are natural (such as chitosan) and polymeric (such as poly(lactic‐co‐glycolic acid) and polyethylene glycol) nanoparticles (NPs). This review discusses the hypotheses for AD pathogenesis and highlights recent advances in the applications of natural and polymeric NPs for treatment. The fundamental and applied aspects of this approach for nasal drug delivery to the brain are reviewed here with thoughts on what is needed for the field to mature also provided.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/adtp.202000076

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 140

Metadata

Authors
Rabiee, N., Ahmadi, S., Afshari, R., Khalaji, S., Rabiee, M., Bagherzadeh, M., Fatahi, Y., Dinarvand, R., Tahriri, M., Tayebi, L., Hamblin, M. R., & Webster, T. J.
Venue
Advanced Therapeutics
Publisher
Wiley
Published
2020-11-30
Volume
4
Issue
3
ISSN
2366-3987 (ISSN-L)
OpenAlex
W3108546506
Cited by
140
References
55
FWCI
5.33
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.